- Integra LifeSciences (NASDAQ:IART) expects Q3 revenue to be in range of $368-$370M indicating a Y/Y decline of ~2.7% on a reported basis and ~1.8% on an organic basis.
- Q3 sales improvement was broad-based across the company’s major franchises.
- The results exceed the company's Q3 revenue outlook range provided in August.
- Q3 results scheduled for Oct. 28, 2020, before market opens.
- https://seekingalpha.com/news/3620263-integra-lifesciences-indicates-q3-prelim-revenue
Tuesday, October 6, 2020
Integra LifeSciences has Q3 prelim revenue
Amwell: Telehealth Use Seen Accelerating Post-Pandemic
Amwell (NYSE: AMWL), a national telehealth leader, today released the results of its annual Physician and Consumer Survey. The results show physicians and consumers expect to use telehealth more often following COVID-19 than they did before the pandemic. Telehealth usage is up considerably in 2020, with 22% of consumers and 80% of physicians having a virtual visit this year, up from 8% and 22%, respectively, in 2019. This adoption is largely driven by a shift to scheduled visits across all specialties, whereas prior to COVID-19 the majority of visits were for on-demand urgent care.
Alexion higher after ambitious agenda on tap for Investor Day
- Ahead of its Investor Day, Alexion Pharmaceuticals (NASDAQ:ALXN) says it expects to boost full-year 2020 revenue guidance by more than $200M.
- 2025 Guidance: Net revenue target increased to $9B-$10B vs. $7.86B previous estimate, with at least 10% annual growth through 2025 and beyond.
- Capital returns: Roughly $3B though 2023.
- Alexion’s pipeline now includes more than 20 development programs, up from four at the end of 2017, with the potential for 10 promising launches by 2023. The company is on track to produce more than five novel INDs by 2025, including two this year.
- Presentation slides are here.
- Webcast beings at 8 ET.
- https://seekingalpha.com/news/3620035-alexion-pharmaceuticals-moves-higher-after-ambitious-agenda-on-tap-for-investor-day
Palihapitiya-led SPAC bringing Clover Health public via merger
- From the press release: Clover Health is a next-generation Medicare Advantage insurance company offering best-in-class plans that combine wide access to healthcare and rich supplemental benefits with low out-of-pocket expenses.
- More: A unique model in health insurance, Clover partners with primary care physicians using its software platform, the Clover Assistant, to deliver data-driven, personalized insights at the point of care.
- The deal with Social Capital Hedosophia (NYSE:IPOC) - Chamath's 3rd SPAC - values Clover at $3.7B, and will provide up to $1.2B in cash proceeds that can be used to grow the business.
- https://seekingalpha.com/news/3620052-chamath-palihapitiya-led-spac-bringing-clover-health-public-via-merger
Chromadex's study with nutritional protocol shows lower recovery time in COVID-19
- ChromaDex (NASDAQ:CDXC) has announced results from a Phase 2 study in patients with mild-to-moderate COVID-19 and reported a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside.
- This additional nutritional support was designed to promote healthy mitochondrial function and reduced average recovery time to 6.6 days in comparison to average placebo recovery time of 9.3 days.
- Patients receiving the nutritional protocol consisting of nicotinamide riboside, L-serine, N-acetyl-L-cysteine, and L-carnitine tartrate also experienced a significant improvement in liver function
- Results from the study were published on the open access preprint publication server medRxiv.org.
Corbus Pharma's lenabasum flunks mid-stage cystic fibrosis study
- Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) slumps 30% premarket in reaction to the announcement of topline results from 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF).
- The study enrolled patients at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF.
- The CF-002 Phase 2b trial did not meet the primary endpoint of a statistically significant reduction in rate of new PEx per subject per 28 weeks. Lenabasum treatment had a favorable safety profile and was well-tolerated.
- The topline data will be presented at the upcoming virtual North American Cystic Fibrosis Conference, taking place October 7-23, 2020.
Vir Biotech/Glaxo's anti-SARS-CoV-2 antibody advances to Phase 3
- Vir Biotechnology (NASDAQ:VIR) and GlaxoSmithKline (NYSE:GSK) have reported global expansion to Phase 3 for the study evaluating VIR-7831/GSK4182136, anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in high-risk patients.
- Expansion will now include additional sites in North America, South America and Europe.
- The Phase 3 portion of the COMET-ICE study in ~1,300 subjects, will assess the safety and efficacy of a single intravenous infusion of VIR-7831 or placebo. Primary efficacy endpoint is the proportion of patients who have progression of COVID-19 as defined by the need for hospitalization or death within 29 days of randomization. Results for primary endpoint is expected in Q1 2021, current estimates at January 2021
- Companies expect to start a Phase 1b/2a trial later this year evaluating VIR-7832, a second investigational SARS-CoV-2 neutralizing antibody that shares the same characteristics as VIR-7831.
- Earlier this year, Vir and GSK collaborated for research and development of COVID-19 treatments.
- https://seekingalpha.com/news/3620093-vir-biotech-glaxos-anti-sars-covminus-2-antibody-advances-to-phase-3
Subscribe to:
Comments (Atom)